The incidence of left ventricular diastolic dysfunction (LVDD) increases in women following menopause, yet the mechanisms are unclear. Because mast cells participate in the pathological processes of various cardiac diseases, we hypothesized that mast cell inhibition would protect against estrogen loss-induced LVDD. The mast cell stabilizer, cromolyn sodium (30 mg/kg/day), or vehicle was administered subcutaneously by osmotic minipump to ovariectomized (OVX) female Fischer344×Brown Norway (F344BN) rats starting at four weeks after surgery. Eight weeks after OVX, systolic blood pressure increased by 20% in OVX vs. sham rats, and this effect was attenuated after four weeks of cromolyn treatment. Also, cromolyn mitigated the adverse reductions in myocardial relaxation (e′) and increases in left ventricle (LV) filling pressures (E/e′), LV mass, wall thicknesses, and interstitial fibrosis from OVX. While cardiac mast cell number was increased after OVX, cardiac chymase activity was not overtly altered by estrogen status and tended to decrease by cromolyn. Contrariwise, Ang II content was greater in hearts of OVX vs. sham rats, and cromolyn attenuated this effect. Taken together, mast cell inhibition with cromolyn attenuates LV remodeling and LVDD in OVX-F344BN rats possibly through actions on the heart level and/or via vasodilatory effects at the vascular level.